[25-NSE] TITAN PHARMACEUTICALS INC SEC Filing

Rhea-AI Filing Summary

Titan Pharmaceuticals, Inc. (TTNP) appears in a Form 25 notification submitted to the SEC by Nasdaq Stock Market LLC indicating removal of a class of the issuer's securities from listing and/or registration under Section 12(b) of the Exchange Act. The filing names the issuer and exchange and gives the issuer's principal office address and phone number. The form includes references to the rule provisions used to strike the class (17 CFR 240.12d2-2 subsections) and contains a standard statement that Nasdaq believes it meets the requirements to file Form 25. The document as provided does not show which specific checkbox was marked, an effective date, or a signed/dated signature block.

Positive

• None.

Negative

• Form 25 filing indicates removal of a class of Titan Pharmaceuticals, Inc. securities from listing/registration on Nasdaq (Form 25 appears filed).
• Document lacks key details: the provided copy does not show which 12d2-2 subsection was checked, no effective date, and the signature/date block is blank.

Insights

Securities Listing Specialist

TL;DR: Nasdaq filed a Form 25 notifying removal of a class of Titan Pharmaceuticals securities; the filing lacks checkbox choice, effective date, and signature details.

The Form 25 supplied identifies Titan Pharmaceuticals, Inc. and Nasdaq Stock Market LLC and references the statutory provisions for removal under 17 CFR 240.12d2-2. The filing text contains the standard Nasdaq certification language but the copy provided omits which specific rule paragraph was selected, any effective removal date, and the executed signature/date block. Those omissions limit the ability to determine timing and the voluntary or involuntary nature of the removal solely from this document.

Corporate Governance Expert

TL;DR: The notice indicates delisting/withdrawal action for TTNP but lacks critical details needed to assess corporate or shareholder implications.

The submitted Form 25 names the issuer and provides contact information, and it cites compliance statements under 17 CFR 240.12d2-2(b) and (c). The absence of a marked rule provision, an effective date, and an executed signature block in the provided text means the document does not establish when or under what precise authority the removal becomes effective, preventing a full governance impact assessment from this content alone.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-13341

Issuer:	TITAN PHARMACEUTICALS INC
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	400 Oyster Point Boulevard, Suite 505
	San Francisco	CALIFORNIA	94080
Telephone number:					(650) 244-4990

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-10-02	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 25 filing say about Titan Pharmaceuticals (TTNP)?

The filing notifies the SEC that Nasdaq submitted a Form 25 to remove a class of Titan Pharmaceuticals securities from listing and/or registration under Section 12(b).

Which exchange is removing TTNP from listing according to the document?

The document names Nasdaq Stock Market LLC as the exchange notifying the SEC of the removal.

Does the filing state the effective date for TTNP's removal from Nasdaq?

No. The provided text does not include an effective date for the removal.

Does the Form 25 show who signed or dated the notification?

No. The signature and date fields in the supplied copy are blank or not populated.

Which rule provisions are referenced in the filing?

The filing references 17 CFR 240.12d2-2 and includes mentions of subsections (a)(1)–(a)(4) and the procedures under paragraphs (b) and (c).